Cholangiocarcinoma

P=N/A, N=40, Recruiting, Peking University | Not yet recruiting --> Recruiting

P3, N=286, Active, not recruiting, Jazz Pharmaceuticals | Recruiting --> Active, not recruiting

We will describe recent findings supporting unique genotype-immunophenotype relationships in iCCA, and the existence of functionally heterogenous subsets of cancer-associated fibroblasts. The ultimate goal is to provide an exhaustive overview of current knowledge and a provoking discussion of therapeutic implications and future directions.

P2, N=30, Recruiting, Elevar Therapeutics | Not yet recruiting --> Recruiting

P=N/A, N=244, Not yet recruiting, MedSIR

P2, N=60, Not yet recruiting, Sir Run Run Shaw Hospital

P2, N=40, Not yet recruiting, OHSU Knight Cancer Institute

P=N/A, N=36, Recruiting, Assistance Publique - Hôpitaux de Paris | Not yet recruiting --> Recruiting | Trial completion date: Apr 2030 --> Oct 2034 | Trial primary completion date: Apr 2028 --> Aug 2028

Notably, CALB2 knockdown significantly sensitized CCA tumors to gemcitabine plus radiotherapy, an effect attenuated by KRT7 overexpression. These findings define a novel H3K4 methylation/CALB2/calcium/NF-κB/KRT7/PD-L1 signaling axis that drives immune suppression and therapy resistance in CCA, highlighting its potential as a multi-target strategy for combined immunotherapy and chemoradiotherapy.

P2, N=126, Completed, Beijing Biostar Pharmaceuticals Co., Ltd. | Recruiting --> Completed | Trial completion date: Dec 2024 --> May 2025 | Trial primary completion date: Mar 2024 --> May 2025

We defined a novel ISG signature in iCCA and identified EGR1 as a critical driver of senescent tumor cells in iCCA.These findings offer new insights into senescent tumor cells and the immunosuppressive microenvironment.

P1, N=48, Recruiting, Washington University School of Medicine | Not yet recruiting --> Recruiting